A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder.

Trial Profile

A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Binge-Eating Disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 12 Apr 2017 Study was planned in Italy, Sweden, USA, Germany, Spain but patients were not recruited from Italy and Sweden.
    • 05 Apr 2017 Results assessing safety and efficacy, published in the Journal of Clinical Psychopharmacology
    • 22 Jul 2015 Results were published in the Shire Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top